Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine-Rituximab

Area of Science:

• Hematology-Oncology
• Clinical Research
• Lymphoma Studies

Background:

• Follicular lymphoma (FL) is a common non-Hodgkin lymphoma, often presenting asymptomatically.
• Advancing therapeutic strategies are improving survival rates for FL patients.
• This case focuses on a symptomatic, stage II bulky low-grade FL presentation.

Observation:

• A 51-year-old male with diabetes presented with symptomatic right inguinal lymphadenopathy.
• Excisional biopsy confirmed stage II bulky symptomatic low-grade FL.
• The patient had no B symptoms like fever, night sweats, or weight loss.

Findings:

• Chemoimmunotherapy with rituximab and bendamustine was administered for six cycles.
• The patient tolerated the treatment well and completed all cycles.
• Follow-up FDG PET/CT scan demonstrated complete remission of the disease.

Implications:

• Bendamustine-Rituximab chemoimmunotherapy is an effective treatment for stage II bulky symptomatic FL.
• Achieving complete remission highlights the efficacy of current therapeutic strategies.
• Long-term surveillance is crucial for confirming sustained remission in FL patients.